Matthias Olbrich

Title: Matthias Olbrich: Innovator in Biocatalytic Processes and Cyclosporin Formulations

Introduction

Matthias Olbrich is a notable inventor based in Reichenberg, Germany. He has made significant contributions to the field of biocatalysis and pharmaceutical formulations. With a total of two patents to his name, Olbrich's work focuses on innovative processes that enhance the production and bioavailability of important compounds.

Latest Patents

Olbrich's latest patents include a process for the enantioselective reduction of 8-chloro-6-oxo-octanoic acid alkyl esters. This invention relates to the production of (R)- or (S)-8-chloro-6-hydroxyoctanoic acid alkyl esters using biocatalytic methods. The desired enantiomers are produced selectively with the help of specific strains of fungi. His second patent involves cyclosporin compositions that offer high bioavailability for oral administration. This formulation includes cyclosporin A and/or cyclosporin G, along with polyethylene glycol esters and alcohols, resulting in a drinkable solution or capsules.

Career Highlights

Throughout his career, Matthias Olbrich has worked with prominent companies such as Novartis AG and Viatris GmbH & Co. KG. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical industry.

Collaborations

Olbrich has collaborated with notable colleagues, including Heinrich Potter and Rainer Gewald. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Matthias Olbrich is a distinguished inventor whose work in biocatalytic processes and pharmaceutical formulations has made a significant impact. His innovative patents reflect his dedication to enhancing the production and effectiveness of important compounds.